Key Takeaways (4-6 bullets, will render as highlighted box)
- The term "GLP-1 inhibitor" is widely searched but pharmacologically incorrect. The drug class is GLP-1 receptor agonist. Agonists activate the receptor. Inhibitors block it.
- Semaglutide, liraglutide, dulaglutide, exenatide, and tirzepatide are all GLP-1 receptor agonists. They mimic the body's natural GLP-1 hormone, slowing digestion, suppressing appetite, and stimulating insulin release.
- A separate class, DPP-4 inhibitors (sitagliptin, linagliptin, saxagliptin), works by inhibiting the enzyme that breaks down GLP-1, indirectly raising GLP-1 levels. This is the closest legitimate use of "inhibitor" in GLP-1 pharmacology.
- The 2021 STEP 1 trial (Wilding et al., NEJM) showed semaglutide produced 14.9% body weight reduction at 68 weeks. The 2022 SURMOUNT-1 trial (Jastreboff et al., NEJM) showed tirzepatide produced 22.5% reduction at the highest dose, the largest weight loss recorded for any approved obesity medication.
- This guide covers what GLP-1 receptor agonists do, how they differ from DPP-4 inhibitors, and the approved drugs in each class.
Direct answer (40-60 words)
There's no FDA-approved drug class called "GLP-1 inhibitor." The actual class is GLP-1 receptor agonist, which includes semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), and tirzepatide (Mounjaro, Zepbound). These activate the GLP-1 receptor to slow digestion, reduce appetite, and trigger insulin release.
Table of contents
- The terminology problem: agonist vs inhibitor
- What GLP-1 actually does in the body
- The full list of GLP-1 receptor agonists
- DPP-4 inhibitors: the legitimate "inhibitor" in this story
- How GLP-1 receptor agonists work step by step
- Approved indications for each drug
- Side effects across the class
- Effectiveness comparison
- Combination GLP-1/GIP and triple agonists
- FAQ
- Sources
- Footer disclaimers
The terminology problem: agonist vs inhibitor
In pharmacology, an agonist is a molecule that binds to a receptor and activates it, producing a biological response. An antagonist or inhibitor is a molecule that binds to a receptor (or to an enzyme) and blocks it, preventing a response.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Semaglutide, tirzepatide, liraglutide, and the rest of this drug class are agonists. They bind to the GLP-1 receptor on pancreatic beta cells, gastric muscles, and brain regions involved in appetite regulation, and they activate that receptor more strongly and for longer than the natural GLP-1 hormone.
The phrase "GLP-1 inhibitor" appears in search queries because patients hear about these drugs being used to "stop" or "reduce" appetite. The intuitive mental model is that something that reduces a behavior must be inhibiting something. The reality is the opposite: these drugs amplify a natural appetite-suppressing signal that the body already produces in small quantities after meals.
A useful way to remember: GLP-1 itself is a satiety hormone. Activating its receptor produces satiety. The drugs that produce satiety are activators (agonists), not blockers.
The term "GLP-1 inhibitor" is sometimes used loosely to mean "a drug that reduces hunger," but in pharmacology textbooks and FDA labeling, the correct term is GLP-1 receptor agonist (often abbreviated GLP-1 RA).
What GLP-1 actually does in the body
Glucagon-like peptide-1 (GLP-1) is a 30-amino-acid peptide hormone secreted by L-cells in the small intestine in response to food intake. The natural hormone has a very short half-life (1 to 2 minutes) because it's rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4) in the bloodstream.
The biological effects of GLP-1 in the few minutes it remains active:
Pancreatic effects:
- Stimulates insulin release from beta cells in a glucose-dependent manner (only when blood sugar is elevated)
- Suppresses glucagon release from alpha cells, reducing hepatic glucose output
- Promotes beta cell preservation and proliferation in animal models
Gastrointestinal effects:
- Slows gastric emptying, prolonging the sensation of fullness after eating
- Reduces gastric acid secretion modestly
- Slows small intestinal transit
Central nervous system effects:
- Acts on hypothalamic and brainstem appetite centers to reduce food intake
- Reduces "food noise" (intrusive thoughts about food) through poorly understood mechanisms involving the area postrema and nucleus tractus solitarius
- May reduce reward-related eating through effects on mesolimbic dopamine circuits
Cardiovascular effects:
- Mild improvements in cardiac output and endothelial function
- Reductions in blood pressure (typically 2 to 5 mmHg systolic)
- Anti-inflammatory effects on vascular tissue
The drug-class GLP-1 receptor agonists were designed to overcome the short half-life of natural GLP-1. Modifications to the peptide structure (acylation, fatty acid attachment, amino acid substitutions) make the drug versions resistant to DPP-4 degradation, extending the half-life from minutes to hours or days.
The full list of GLP-1 receptor agonists
The FDA-approved GLP-1 receptor agonists in the U.S. as of 2026:
| Drug | Brand names | Indication | Half-life | Frequency |
|---|---|---|---|---|
| Exenatide | Byetta | Type 2 diabetes | ~2.4 hours | Twice daily |
| Exenatide ER | Bydureon | Type 2 diabetes | ~2 weeks (sustained) | Once weekly |
| Liraglutide | Victoza | Type 2 diabetes | ~13 hours | Once daily |
| Liraglutide | Saxenda | Chronic weight management | ~13 hours | Once daily |
| Dulaglutide | Trulicity | Type 2 diabetes | ~5 days | Once weekly |
| Semaglutide (injectable) | Ozempic | Type 2 diabetes | ~7 days | Once weekly |
| Semaglutide (injectable) | Wegovy | Chronic weight management | ~7 days | Once weekly |
| Semaglutide (oral) | Rybelsus | Type 2 diabetes | ~7 days | Once daily (oral) |
| Tirzepatide (dual GLP-1/GIP) | Mounjaro | Type 2 diabetes | ~5 days | Once weekly |
| Tirzepatide (dual GLP-1/GIP) | Zepbound | Chronic weight management | ~5 days | Once weekly |
Tirzepatide is technically a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. The GIP component adds a complementary mechanism that, in clinical trials, has produced larger weight loss than pure GLP-1 agonists at comparable durations.
The shift from twice-daily exenatide (approved 2005) to once-weekly semaglutide (approved 2017) and now once-weekly tirzepatide reflects the drug class's progressive optimization of half-life and receptor selectivity.
DPP-4 inhibitors: the legitimate "inhibitor" in this story
The closest legitimate use of "inhibitor" in GLP-1 pharmacology is the DPP-4 inhibitor class. These don't activate GLP-1 receptors directly. They block the enzyme that breaks GLP-1 down, allowing the body's own natural GLP-1 to remain active longer.
| Drug | Brand name | Mechanism | Indication |
|---|---|---|---|
| Sitagliptin | Januvia | DPP-4 inhibition | Type 2 diabetes |
| Saxagliptin | Onglyza | DPP-4 inhibition | Type 2 diabetes |
| Linagliptin | Tradjenta | DPP-4 inhibition | Type 2 diabetes |
| Alogliptin | Nesina | DPP-4 inhibition | Type 2 diabetes |
DPP-4 inhibitors raise post-meal GLP-1 levels modestly (about 2 to 3 fold above baseline), which is much less dramatic than the receptor activation produced by direct GLP-1 receptor agonists. As a result, DPP-4 inhibitors:
- Lower HbA1c by about 0.5 to 0.8 percentage points (vs 1.0 to 2.0 for GLP-1 agonists)
- Don't typically produce meaningful weight loss
- Don't slow gastric emptying enough to cause nausea
- Are oral pills rather than injections
DPP-4 inhibitors are useful for patients with mild type 2 diabetes who can't tolerate the GI side effects of injectable GLP-1 agonists or who don't need the additional weight loss benefit. They are not used for weight management because the effect on appetite is too small to drive meaningful weight changes.
If a patient or clinician asks about "GLP-1 inhibitors" in the context of diabetes treatment, they may actually mean DPP-4 inhibitors. In the context of weight management, they almost certainly mean GLP-1 receptor agonists.
How GLP-1 receptor agonists work step by step
The end-to-end mechanism, simplified:
Step 1: The drug binds to the GLP-1 receptor. The GLP-1 receptor is a G-protein coupled receptor present on pancreatic beta cells, gastric smooth muscle, vagal afferent neurons, and hypothalamic and brainstem nuclei involved in appetite regulation.
Step 2: Receptor activation triggers downstream signaling. Cyclic AMP rises, protein kinase A activates, and a cascade of signaling events follows. In beta cells, this primes insulin release. In gastric muscle, this slows contraction. In appetite centers, this enhances satiety signals.
Step 3: After a meal, multiple effects converge. Insulin is released in response to the rising blood glucose, but with stronger amplitude than would occur without the drug. Glucagon is suppressed. Stomach contents leave the stomach more slowly, prolonging the sense of fullness. The brain registers reduced hunger.
Step 4: Between meals, appetite signaling is altered. Food noise (intrusive thoughts about food) decreases for many patients. Reward eating (eating for emotional or hedonic reasons) is reduced. Total caloric intake drops.
Step 5: Over weeks to months, body composition changes. Caloric deficit drives weight loss, primarily of fat mass. Some loss of lean mass occurs but tends to be less than caloric-deficit-only diets, possibly due to GLP-1's effects on protein-sparing pathways.
Step 6: Long-term metabolic effects emerge. Insulin sensitivity improves. HbA1c drops. Cardiovascular markers (blood pressure, lipids, inflammatory markers) improve. The 2023 SELECT trial (Lincoff et al., NEJM 2023) showed semaglutide reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease and obesity.
Approved indications for each drug
The FDA approval landscape for GLP-1 receptor agonists has expanded steadily.
Type 2 diabetes: all GLP-1 receptor agonists are approved for this indication. The class is now a first-line option in many treatment guidelines, especially for patients with cardiovascular or kidney disease.
Chronic weight management (obesity): Wegovy (semaglutide 2.4 mg), Saxenda (liraglutide 3.0 mg), and Zepbound (tirzepatide) are FDA-approved. Eligibility typically requires BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, sleep apnea).
Cardiovascular risk reduction: Wegovy received FDA approval in 2024 for reducing major adverse cardiovascular events in adults with established cardiovascular disease and obesity, based on the SELECT trial.
Sleep apnea: Zepbound received FDA approval in 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trials.
Heart failure with preserved ejection fraction: Wegovy received FDA approval in 2024 for reducing symptoms in adults with HFpEF and obesity, based on the STEP-HFpEF trials.
Chronic kidney disease in type 2 diabetes: Ozempic received FDA approval in 2025 for reducing kidney disease progression risk based on the FLOW trial (Perkovic et al., NEJM 2024).
Pediatric obesity: Wegovy is approved for ages 12 and up. Saxenda is approved for ages 12 and up. Zepbound has pediatric data emerging from SURMOUNT-Adolescents and is expected to expand.
The expansion from diabetes to weight management to cardiovascular and kidney indications reflects the broad metabolic effects of GLP-1 receptor activation.
Side effects across the class
GI side effects dominate the side effect profile. The pattern is consistent across all GLP-1 receptor agonists, though severity and frequency differ.
| Side effect | Typical incidence | Notes |
|---|---|---|
| Nausea | 35-45% | Peaks during dose escalation, fades with adaptation |
| Diarrhea | 20-30% | More common with semaglutide than with shorter-acting agents |
| Vomiting | 10-25% | Often associated with high-fat meals |
| Constipation | 15-25% | Hydration and fiber help |
| Abdominal pain | 15-20% | Usually mild and transient |
| Headache | 10-15% | Often during initial weeks |
| Injection site reactions | 5-10% | Mild redness, swelling, occasional itching |
Less common but clinically important:
- Pancreatitis (rare, ~0.1-0.4% in trials). Discontinue if suspected.
- Gallbladder disease (slight increase, especially with rapid weight loss). Cholecystitis and cholelithiasis incidence about 1.6 to 2.0 percentage points higher than placebo in long trials.
- Medullary thyroid carcinoma (boxed warning based on rodent studies, no confirmed human signal).
- Hypoglycemia (uncommon as monotherapy, more common in combination with insulin or sulfonylureas).
- Aspiration during anesthesia (American Society of Anesthesiologists 2023 guidance recommends holding GLP-1 agonists for at least one week before elective surgery requiring general anesthesia, due to delayed gastric emptying).
Most side effects can be managed with dose titration, dietary adjustments (smaller meals, lower fat content, avoiding lying flat after eating), and time. Discontinuation rates for GI intolerance are typically 4 to 7% in clinical trials.
Effectiveness comparison
Head-to-head and trial-by-trial weight loss data:
| Drug and dose | Trial | Mean weight change at endpoint | Duration |
|---|---|---|---|
| Liraglutide 3.0 mg daily | SCALE | -8.0% | 56 weeks |
| Semaglutide 2.4 mg weekly | STEP 1 | -14.9% | 68 weeks |
| Semaglutide 2.4 mg weekly | STEP 4 | -17.4% (continued) vs -5.0% (placebo) | 68 weeks |
| Tirzepatide 5 mg weekly | SURMOUNT-1 | -15.0% | 72 weeks |
| Tirzepatide 10 mg weekly | SURMOUNT-1 | -19.5% | 72 weeks |
| Tirzepatide 15 mg weekly | SURMOUNT-1 | -20.9% (intent-to-treat) / -22.5% (per protocol) | 72 weeks |
| Tirzepatide vs semaglutide head-to-head | SURMOUNT-5 | Tirzepatide produced ~20.2% loss vs semaglutide's 13.7% at 72 weeks | 72 weeks |
For type 2 diabetes (HbA1c reduction):
| Drug | Typical HbA1c reduction | Trial reference |
|---|---|---|
| Exenatide BID | 0.8-1.0 percentage points | DURATION programs |
| Liraglutide 1.8 mg | 1.0-1.5 percentage points | LEAD trials |
| Dulaglutide 1.5 mg | 1.0-1.5 percentage points | AWARD trials |
| Semaglutide 1.0 mg | 1.5-2.0 percentage points | SUSTAIN trials |
| Tirzepatide 15 mg | 2.0-2.5 percentage points | SURPASS trials |
Tirzepatide's dual mechanism (GLP-1 plus GIP receptor activation) produces the largest effect on both weight and HbA1c in head-to-head data. Pure GLP-1 receptor agonists are still highly effective and may be preferred when supply, cost, or specific side effect profile favors them.
Combination GLP-1/GIP and triple agonists
The drug class is evolving rapidly. The next-generation molecules under development or recently approved:
Tirzepatide (already approved): dual GLP-1 and GIP receptor agonist. Mounjaro for diabetes, Zepbound for weight management.
Retatrutide (Phase 3): triple agonist for GLP-1, GIP, and glucagon receptors. Phase 2 data showed -24.2% weight loss at 48 weeks at the highest dose (Jastreboff et al., NEJM 2023), the largest result ever reported for an obesity medication. FDA approval timing is uncertain as of 2026.
Maridebart cafraglutide (MariTide) (Phase 3): GLP-1 agonist with amylin receptor activity. Monthly dosing potential.
Survodutide (Phase 3): GLP-1 and glucagon dual agonist.
CagriSema (Phase 3): semaglutide combined with cagrilintide (an amylin analog). Phase 3 readout expected 2025-2026.
The rapid pace of new molecules means the GLP-1 receptor agonist class is best understood as a foundation rather than a final answer. Effects on weight, glycemic control, cardiovascular outcomes, and other metabolic endpoints are likely to expand further.
FAQ
What is a GLP-1 inhibitor? "GLP-1 inhibitor" is a misnomer. The actual drug class is GLP-1 receptor agonist, which activates the GLP-1 receptor. Drugs in the class include semaglutide, liraglutide, dulaglutide, exenatide, and tirzepatide. A separate class, DPP-4 inhibitors, blocks the enzyme that breaks down natural GLP-1.
What's the difference between a GLP-1 agonist and a DPP-4 inhibitor? GLP-1 agonists are injected (mostly) and directly activate the GLP-1 receptor, producing strong effects on weight and blood sugar. DPP-4 inhibitors are oral pills that prevent breakdown of natural GLP-1, producing milder effects on blood sugar with little weight effect.
Are Ozempic and Wegovy GLP-1 inhibitors? No. Both are GLP-1 receptor agonists. They activate the GLP-1 receptor rather than blocking it. The active ingredient in both is semaglutide.
How long does GLP-1 stay in your system? Natural GLP-1 has a half-life of 1 to 2 minutes. The drug versions are designed to last much longer: liraglutide 13 hours, dulaglutide 5 days, semaglutide 7 days, tirzepatide 5 days. After stopping, it takes about 5 half-lives for the drug to clear, so semaglutide takes roughly 5 weeks to leave the system.
Why do GLP-1 receptor agonists cause nausea? Nausea results from delayed gastric emptying and direct effects on the brain's nausea centers (area postrema and nucleus tractus solitarius). The slow titration schedule is designed to allow these systems to adapt. Most nausea fades after the first 4 to 8 weeks of each dose.
Can you take a GLP-1 receptor agonist long-term? Yes. Clinical trials have followed patients for 2 to 5 years on continuous treatment without unexpected long-term safety issues. Discontinuation typically results in weight regain over 6 to 12 months, which has led many clinicians to consider obesity treatment a chronic therapy rather than a short-term intervention.
What's the most effective GLP-1 receptor agonist for weight loss? Tirzepatide produces the largest weight loss in head-to-head trials, with 20% to 22% reduction at 72 weeks at the highest dose. Semaglutide produces about 15%. Liraglutide produces about 8%. Tirzepatide's dual GLP-1/GIP mechanism appears to outperform pure GLP-1 agonism for both weight and HbA1c.
Are GLP-1 receptor agonists safe for the heart? Yes, and they may improve cardiovascular outcomes. The SELECT trial showed semaglutide reduced major adverse cardiovascular events by 20% in patients with established CVD and obesity. The LEADER and REWIND trials showed similar benefits with liraglutide and dulaglutide in type 2 diabetes.
Can you take GLP-1 receptor agonists if you have type 1 diabetes? Generally no. The drug class is approved for type 2 diabetes, not type 1. Type 1 diabetes patients still produce no insulin and need insulin replacement; GLP-1 receptor agonists work primarily by enhancing endogenous insulin response.
Do GLP-1 receptor agonists cause thyroid cancer? There is a boxed warning based on rodent studies showing C-cell tumors. Human data has not confirmed an increased risk in clinical trials and post-marketing surveillance. Patients with personal or family history of medullary thyroid carcinoma or MEN-2 syndrome should not take GLP-1 receptor agonists.
What happens when you stop a GLP-1 receptor agonist? Plasma drug levels decline over 4 to 5 weeks. Appetite returns, often with intensity ("food noise" coming back). Weight regain averages two-thirds of lost weight within a year if no other intervention is in place. Discussing a maintenance strategy with your clinician before stopping is recommended.
Is there a GLP-1 inhibitor for any condition? Not in clinical use. Researchers have explored GLP-1 receptor antagonists experimentally, but no GLP-1-blocking drug is FDA-approved for any indication. The clinical demand has been entirely on the agonist side.
Sources
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
- Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375(4):311-322.
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844.
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE Obesity). N Engl J Med. 2015;373(1):11-22.
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity. N Engl J Med. 2023;389(6):514-526.
- Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391(2):109-121.
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515.
- American Society of Anesthesiologists. Consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists. ASA, 2023.
- American Diabetes Association. Standards of Medical Care in Diabetes - 2024. Diabetes Care. 2024;47(Suppl 1).
- U.S. Food and Drug Administration. Wegovy (semaglutide injection) prescribing information. 2024 revision.
- U.S. Food and Drug Administration. Zepbound (tirzepatide injection) prescribing information. 2024 revision.
Footer disclaimers (all 4 verbatim)
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro, Zepbound, and Trulicity are registered trademarks of Eli Lilly and Company. Victoza, Saxenda, Byetta, and Bydureon are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.